首页> 外文期刊>Leukemia and lymphoma >Double G0/G1 peak in the DNA histogram of aberrant marker positive acute leukemia patients is associated with a poor clinical outcome.
【24h】

Double G0/G1 peak in the DNA histogram of aberrant marker positive acute leukemia patients is associated with a poor clinical outcome.

机译:异常标志物阳性的急性白血病患者的DNA直方图中的双G0 / G1峰与不良的临床预后相关。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In order to investigate the relationship between aberrant marker expression and DNA ploidy, 61 adult patients with acute leukemia (39 AML and 22 ALL) were studied. Aberrant marker expression was observed in 20 patients (16/39 of AML and 4/22 of ALL patients). In flow cytometric DNA analysis aneuploidy was observed in 18 patients (9/39 of AML and 9/22 of ALL patients). The incidence of aneuploidy in patients with aberrant marker expression was 35% whereas this was 26.8% in patients without aberrant marker expression. Furthermore, 7 patients with aberrant marker expression showed an aneuploid, double G0/G1 peaks appearance whereas the remaining 11 patients with aberrant marker expression had euploid DNA content. Double G0/G1 appearance was not observed in patients without aberrant marker expression. Further analyses revealed that this did not correlate with apoptosis. All 7 patients, who had both aberrant marker expression and double G0/G1 peak had a poor clinical outcome with a short survival and all died within three months whereas three-months survival was 67% for AML, 69% for ALL patients and 81% for patients with aberrant marker expression respectively (p<0.01). Our data indicate that the evaluation of the DNA ploidy in patients with aberrant marker expression may be of prognostic importance.
机译:为了研究异常标志物表达与DNA倍性之间的关系,研究了61例成人急性白血病(39 AML和22 ALL)。在20例患者中观察到异常的标志物表达(AML的16/39和ALL患者的4/22)。在流式细胞仪DNA分析中,在18例患者(AML的9/39和ALL患者的9/22)中观察到非整倍性。具有异常标志物表达的患者的非整倍性发生率为35%,而没有异常标志物表达的患者为26.8%。此外,7例异常标记物表达的患者显示非整倍体,双G0 / G1峰出现,而其余11例异常标记物表达的患者具有整倍体DNA含量。没有异常标志物表达的患者未观察到双G0 / G1出现。进一步的分析表明,这与细胞凋亡无关。 7例既有异常标志物表达又有双重G0 / G1峰的患者临床预后较差,生存期较短,均在3个月内死亡,而AML的3个月生存率为67%,ALL的为69%,ALL的为81%分别用于标记表达异常的患者(p <0.01)。我们的数据表明,在标记物表达异常的患者中评估DNA倍性可能对预后具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号